Abstract:Huntington's disease (HD) is a heritable neurological disorder that affects cognitive and motor performance in patients carrying the mutated huntingtin (HTT) gene. In mouse models of HD, previous reports showed a significant increase in spontaneous GABAA receptor-mediated synaptic activity in striatal spiny projection neurons (SPNs). In this study, using optogenetics and slice electrophysiology, we examined the contribution of γ-aminobutyric acid (GABA)-ergic parvalbumin (PV)- and somatostatin (SOM)-expressing interneurons to the increase in GABA neurotransmission using the Q175 (heterozygote) mouse model of HD. Patch clamp recordings in voltage-clamp mode were performed on SPNs from brain slices of presymptomatic (2 months) and symptomatic (8 and 12 months) Q175 mice and wildtype (WT) littermates. While inhibitory postsynaptic currents (IPSCs) evoked in SPNs following optical activation of PV- and SOM-expressing interneurons differed in amplitude, no genotype-dependent differences were observed at all ages from both interneuron types; however, responses evoked by either type were found to have faster kinetics in symptomatic mice. Since SOM-expressing interneurons are constitutively active in striatal brain slices, we then examined the effects of acutely silencing these neurons in symptomatic mice with enhanced Natronomonas pharaonis halorhodopsin (eNpHR). Optically silencing SOM-expressing interneurons resulted in a greater decrease in the frequency of spontaneous IPSCs (sIPSCs) in a subset of SPNs from Q175 mice compared to WTs, suggesting that SOM-expressing interneurons are the main contributors to the overall increased GABA synaptic activity in HD SPNs. Additionally, the effects of activating GABAB and cannabinoid (CB1) receptors were investigated to determine whether these receptors were involved in modulating interneuron-specific GABA synaptic transmission and if this modulation differed in HD mice. When selectively activating PV- and SOM-expressing interneurons in the presence of the CB1 receptor agonist WIN-55,212, the magnitudes of the evoked IPSCs in SPNs decreased for both interneuron types although this change was less prominent in symptomatic Q175 SPNs during SOM-expressing interneuron activation. Overall, these findings show that dysfunction of SOM-expressing interneurons contributes to the increased GABA synaptic activity found in HD mouse models and that dysregulation of the endocannabinoid system may contribute to this effect.

Dysregulation of protein SUMOylation networks in Huntington's disease R6/2 mouse striatum

Protein Expression in the Striatum and Cortex Regions of the Brain for A Mouse Model of Huntington'S Disease

Disposition of Proteins and Lipids in Synaptic Membrane Compartments is Altered in Q175/Q7 Huntington’s Disease Mouse Striatum

Impaired Ubiquitin–proteasome System Activity in the Synapses of Huntington's Disease Mice

Quantitative Phosphoproteomics Reveals Extensive Protein Phosphorylation Dysregulation in the Cerebral Cortex of Huntington’s Disease Mice Prior to Onset of Symptoms

Progressive alterations in polysomal architecture and activation of ribosome stalling relief factors in a mouse model of Huntington's disease

Developmental alterations of indirect-pathway medium spiny neurons in mouse models of Huntington's disease.

Major Contribution of Somatostatin-Expressing Interneurons and Cannabinoid Receptors to Increased GABA Synaptic Activity in the Striatum of Huntington’s Disease Mice

The Urine Metabolome of R6/2 and zQ175DN Huntington's Disease Mouse Models

Ubiquitin-Activating Enzyme Activity Contributes to Differential Accumulation of Mutant Huntingtin in Brain and Peripheral Tissues

Integrated multi-omics analysis of Huntington disease identifies pathways that modulate protein aggregation

Progressive alterations in polysomal architecture and activation of ribosome stalling relief factors in a mouse model of Huntington’s disease

Metabolic disruption identified in the Huntington’s disease transgenic sheep model

Early TNF-Dependent Regulation of Excitatory and Inhibitory Synapses on Striatal Direct Pathway Medium Spiny Neurons in the YAC128 Mouse Model of Huntington's Disease

Global Proteome and Ubiquitinome Changes in the Soluble and Insoluble Fractions of Q175 Huntington Mice Brains

Nucleolar stress controls mutant Huntington toxicity and monitors Huntington’s disease progression

Systematic Uncovering of Multiple Pathways Underlying the Pathology of Huntington Disease by an Acid-Cleavable Isotope-Coded Affinity Tag Approach

Striatal-enriched Protein Tyrosine Phosphatase Expression and Activity in Huntington's Disease: a STEP in the Resistance to Excitotoxicity.

Neuroimmune pathways involvement in neurodegeneration of R6/2 mouse model of Huntington's disease

Thalamocortical Projections Are Significantly Impaired in the R6/2 Mouse Model of Huntington's Disease

Synaptic Mutant Huntingtin Inhibits Synapsin-1 Phosphorylation And Causes Neurological Symptoms